Recursion Pharmaceuticals, Inc. (RXRX) Gross margin 2020–2025
Recursion Pharmaceuticals, Inc. (RXRX) gross margin by fiscal year — reported gross profit divided by reported revenue.
5.0%FY2025 · since FY2020: 100.0% → 5.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 5.0% | -18.1 pp |
| FY2024 | 23.1% | +18.7 pp |
| FY2023 | 4.5% | +25.6 pp |
| FY2022 | -21.2% | -121.2 pp |
| FY2021 | 100.0% | +0.0 pp |
| FY2020 | 100.0% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More RXRX financial trends
RXRX RevenueRXRX Net incomeRXRX Net marginRXRX Gross profitRXRX Operating incomeRXRX Operating marginRXRX Operating cash flowRXRX Free cash flowRXRX Capital expendituresRXRX Return on equityRXRX Stock buybacksRXRX Dividends paidRXRX Total assetsRXRX Total liabilitiesRXRX Shareholders’ equityRXRX overview →